New staging systems of dementia require adaptation of disease management programs and adequate staging instruments. 5 key findings →
Participants: 6,109 Evidence: low
Full summary, score breakdown and related studies → Original source
34,580 published Alzheimer's and dementia studies, each summarized in plain English, scored out of 100 and linked to the original paper.
New staging systems of dementia require adaptation of disease management programs and adequate staging instruments. 5 key findings →
Participants: 6,109 Evidence: low
Full summary, score breakdown and related studies → Original source
Patients with AD exhibit significantly higher CSF τ protein levels than healthy controls or patients with VaD in the Chinese population. 3 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Motor inactivity is typical in the later stages of Alzheimer's disease although there is evidence that physical exercise can reduce depression and enhance performance of daily activities. 2 key findings →
Participants: 21 Evidence: low
Full summary, score breakdown and related studies → Original source
Women and racial/ethnic minority dementia caregivers have unique caregiving experiences and support needs. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Retinal nerve fiber layer (RNFL) thickness, ganglion cell layer (GCL) thickness, and macular volume (MV) utilizing spectral domain optical coherence tomography (SD-OCT) were compared among patients with Alzheimer's disease (AD) dementia, non-Alzheimer's disease (non-AD) dementia, amnestic mild cognitive impairment (aMCI), Parkinson's disease (PD), and age- and sex-matched controls in a cross-sectional cohort study. 1 key finding →
Design: cohort study Participants: 116 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Despite evidence of ethnic differences in family caregivers' experiences, the extent to which caregiver interventions are culturally tailored to address these differences is unknown. 1 key finding →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The COVID-19 pandemic forced adult day services (ADS) to close and abruptly end in-person services to clients. 5 key findings →
Design: randomized controlled trial Participants: 19 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Twelve studies were considered for analysis. 3 key findings →
Design: meta-analysis Participants: 535 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Compared to participants with no APOE-E4 alleles, participants with 1 allele had better thresholds at 4.0 kHz (β = -2.72 dB, P = .013) and 8.0 kHz (β = -3.05 kHz, P = .006), and participants with 2 alleles had better hearing thresholds at 1.0 kHz (β = -8.56 dB, P = .021). 2 key findings →
Design: cross-sectional Participants: 1,833 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer disease (AD) may develop after the onset of type 2 diabetes mellitus (T2DM), and the risk of AD may depend on the antidiabetic drug administered. 2 key findings →
Participants: 85 Evidence: low
Full summary, score breakdown and related studies → Original source
The objective of this study was to compare the effect of multisensory stimulation environment (MSSE) and one-to-one activity sessions in the symptomatology of elderly individuals with severe dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
After adjusting for age, race, and gender, persons with Alzheimer's disease and dementia associated with medical conditions were less likely to be diagnosed with hypertension, diabetes, congestive heart failure, and atrial fibrillation than were controls. 5 key findings →
Participants: 15,013 Evidence: low
Full summary, score breakdown and related studies → Original source
Moderate/severe hearing loss was significantly associated with lower composite z score in males (β = -28.67, 95% confidence interval [95% CI] = -57.13 to -0.20) but not in females (β = -8.82, 95% CI = -36.61 to 18.96). 3 key findings →
Participants: 655 Evidence: low
Full summary, score breakdown and related studies → Original source
The spectrum of cognitive decline in the elderly ranges from what can be classified as normal cognitive decline with aging to subjective cognitive impairment to mild cognitive impairment (MCI) to dementia. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Primary progressive aphasia (PPA) is a clinical dementia syndrome with early symptoms of language dysfunction. 1 key finding →
Participants: 16 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
One hundred sixteen participants (Aβ- cognitively normal [CN], n = 35; Aβ- aMCI, n = 42; Aβ+ aMCI, n = 39) were included. 5 key findings →
Participants: 35 Evidence: low
Full summary, score breakdown and related studies → Original source
The relationships between caregiver burden as measured with the Burden Scale for Family Caregivers-short form and 6 characteristics of caregivers caring for patients with dementia were investigated for caregivers from England (n = 36), Finland (n = 42), and Greece (n = 46) using survey data. 1 key finding →
Participants: 36 Evidence: low
Full summary, score breakdown and related studies → Original source
The final cohort consisted of 91 302 Medicare beneficiaries with an ADRD diagnosis. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Cognitive and depressive symptoms co-occur, complicating detection of mild cognitive impairment (MCI) and early dementia. 5 key findings →
Participants: 72 Evidence: low
Full summary, score breakdown and related studies → Original source
To understand family members' perspectives on person- and family-centered end-of-life care provided to nursing home (NH) residents with advanced dementia, we conducted a qualitative follow-up interview with 16 respondents who had participated in an earlier prospective study, Choices, Attitudes, and Strategies for Care of Advance Dementia at End of Life (CASCADE). 1 key finding →
Participants: 16 Evidence: low
Full summary, score breakdown and related studies → Original source
In established dementia, administration of the CogState tasks appears sensitive to cognitive impairment in dementia. 1 key finding →
Participants: 23 Evidence: low
Full summary, score breakdown and related studies → Original source
Triggering receptor expressed on myeloid cells 2 (TREM2) is upregulated in activated microglia and may be related to cognitive decline in patients with Alzheimer's disease (AD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
In view of the paucity of data on cerebrospinal fluid (CSF) biomarkers in Chinese patients, we evaluated the validity of tau, phosphorylated tau 181 (p-tau-181), amyloid β 42 (Aβ42), and Aβ40 proteins in Chinese patients with Alzheimer's disease (AD). 3 key findings →
Participants: 24 Evidence: low
Full summary, score breakdown and related studies → Original source
The results of the extended model show that social influence, effort expectancy, facilitating conditions, and behavioral intention (BI) all had P P value for RC and TA was greater than .05, hence were insignificant. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) is a neurodegenerative disorder for which there is no cure. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 34,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 34,580 records, built mostly from automated pulls of Europe PMC (68.8% of the library) and OpenAlex (14.7%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,050 records (3% of the library) are not peer-reviewed — 966 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events
Last updated